Current Report Filing (8-k)
November 13 2018 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
November 13, 2018
EYEGATE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36672
|
|
98-0443284
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
271 Waverley Oaks Road
Suite 108
Waltham, MA
|
|
02452
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(781) 788-9043
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
x
On November 13, 2018, EyeGate Pharmaceuticals, Inc. (the “Company”)
issued two press releases announcing (i)
top line data from a study evaluating the potential
of the Company’s Ocular Bandage Gel (“OBG”) product candidate in patients with punctate epitheliopathies due
to pathologies such as dry eye, and (ii) top line data from a study evaluating the potential of OBG in patients with large corneal
epithelial defects following photorefractive keratectomy, or PRK, surgery
.
The press releases are filed as Exhibit 99.1 and Exhibit 99.2
and investors should read each press release in its entirety, including the cautionary statements regarding forward looking statements
therein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The Company hereby files the following exhibits:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
EYEGATE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Stephen From
|
|
|
Stephen From
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
Date: November 13, 2018
|
Exhibit Index
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2023 to Apr 2024